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ABSTRACT
Intestinal failure is a rare life-threatening condition that results in the inability to maintain normal
growth and hydration status by enteral nutrition alone. Although parenteral nutrition and whole or-
gan allogeneic transplantation have improved the survival of these patients, current therapies are
associated with a high risk for morbidity andmortality. Development of methods to propagate adult
human intestinal stem cells (ISCs) and pluripotent stem cells raises the possibility of using stem cell-
based therapy for patients with monogenic and polygenic forms of intestinal failure. Organoids have
demonstrated the capacity to proliferate indefinitely and differentiate into the various cellular line-
ages of the gut.Genome-editing techniques, including theoverexpressionof the corrected formof the
defective gene, or the use of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9
to selectively correct the monogenic disease-causing variant within the stem cell, make autologous
ISC transplantation a feasible approach. However, numerous techniques still need to be further op-
timized, includingmore robust ex vivo ISC expansion, native ISC ablation, and engraftment protocols.
Large-animal models can to be used to develop such techniques and protocols and to establish the
safety of autologous ISC transplantation because outcomes in suchmodels can be extrapolatedmore
readily to humans. STEM CELLS TRANSLATIONALMEDICINE 2016;5:1–11
SIGNIFICANCE
The field of intestinal stem cell biology has exploded over the past 5 years with discoveries related to
in vivo and in vitro stem cell identity and function. The goal of this review article is to highlight the
potential useof these cells to treat various epithelial disorders of the gut anddiscuss the various road-
blocks that will be encountered in the coming years.
INTRODUCTION
Intestinal failure (IF) is a raremultifactorial clinical
condition that results in patients’ inability to sus-
tain normal growth and nutritional and hydration
status without the use of parenteral nutrition
(PN) [1, 2]. The patients with IF can be classified
by whether the small bowel is reduced or of nor-
mal length. Short bowel syndrome (SBS) is the
most common cause of IF, and it usually results
from extensive bowel resection, frequently due
to necrotizing enterocolitis, congenital anomaly
(e.g., gastroschisis or intestinal atresia), and is-
chemia from malrotation and volvulus [2]. In
adults and older children, SBS is commonly asso-
ciated with Crohn’s disease, resulting in severe
transmural inflammation that necessitates surgi-
cal resection. Therefore, SBS-associated IF occurs
across the age spectrum and is generally associ-
ated with prematurity and polygenetic disorders.
In contrast, patients with the non-SBS form of
IF have normal or reduced small bowel surface
area despite a normal-length bowel. A growing
number of congenital disorders of the gut epithe-
lium result in a generalized loss of nutrient absorp-
tion capacity (Table 1). Among the disorders that
alter the villus-crypt axis and lead to adecline in sur-
face area are microvillus inclusion disease (MVID)
[3] and congenital tufting enteropathy (CTE) [4,
5]. Several disorders that alter intestinal endocrine
cells differentiation or function lead to IF despite a
normal surface area [1, 6, 7]. Patients with nonepi-
thelial forms of IF also include a broad group of
those with severe dysmotility disorders, such as
Hirschsprung’s disease and chronic intestinal
pseudo-obstruction syndrome, that have vari-
ous abnormalities in smoothmuscle and enteric
neuronal cell differentiation or function [7]. Simi-
larly, an ever-expanding number of immunologic
disorders, suchas IPEX (immunedysfunction, poly-
endocrinopathy, enteropathy, X-linked), can lead
to IF, and immunomodulatory treatment or bone
marrow transplantation are efficacious in a limited
number of patients [3]. Most non-SBS forms of IF
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are caused by a monogenic disorder, which may be amendable to
stem cell-based therapy.
Currentmanagement of patients with IF involves close dietary
modulation of PN and enteral feeds, medical therapy, and surgical
intervention. Parenteral nutrition is themainstay of therapy for pa-
tientswith IF; however, its long-termuse is associatedwith various
significant limitations, including IF-associated liver disease [8],
catheter-related infections [9], and central venous thrombosis
[10]. In selected patients with specific features that may shorten
survival or complicate PN, allogeneic intestinal and/or liver trans-
plantation is potentially a life-saving therapeutic alternative [11].
However, intestinal transplantation is associated with a high mor-
tality;more thanhalf thepatientsdie awaiting transplantation, and
the 5-year survival of patients undergoing transplantation is ap-
proximately 60% [12]. To mitigate the risk for allograft rejection,
lifelong potent immunomodulatory agents with narrow therapeu-
tic index are required; therefore, these therapies not unexpectedly
predispose patients to severe recurrent infections and the risk for
various post-transplant malignancies [3, 13]. Thus, the develop-
ment of alternative therapies is needed to improve the long-
term management options in patients with IF.
Intestinal stemcell (ISC) researchhasmadesignificantstrides in
improving the understanding of the unique cell populations
involved in self-renewal and differentiation during homeostatic
and stressed conditions [14]. Various methods can be used to iso-
late and expand both human somatic ISCs and induced pluripotent
stem cells (iPSCs) in intestinal organoids that recapitulate the na-
tive epithelium and can be grown on various extracellularmatrices
in a two- (2D) or three-dimensional (3D) configuration [15, 16].
Concurrent development of gene-editing techniques has also
made treatment of monogenic disorders more likely. Indeed, the
first functional restoration experiments have been performed in
ISCs derived from patients with cystic fibrosis using CRISPR (clus-
tered regularly interspaced short palindromic repeat)/Cas9
genome editing [17]. This corrected disease-causing mutation indi-
cated the therapeutic potential of combining reconstituted intes-
tinal enteroids and genome editing technology. Gene-corrected
autologous ISC transplantation may be an alternative long-term
solution for patientswith IF secondary to defects of the gut epithe-
lium [18–20]. However, several significant hurdles remain before
genetically corrected reconstituted intestinal enteroids can be
used inpatients, including the development of ISC ablation and im-
plantation protocols, and to address safety concerns.
Here we review the current models of stem cell-driven intes-
tinal epithelial regeneration, with particular emphasis on human
models; discuss how advancements in ISCs and gene editing can
Table 1. Causes of intestinal failure due to congenital disorders of the gut epithelium
Clinical disorder MIM no.
Inheritance
pattern Gene
Epithelial
Congenital tufting
enteropathy
613217 AR EpCAM
Microvillus inclusion
disease
251850; 600876 AR MYO5b; STX3
DGAT1 deficiency 615863 AR DGAT1
Syndromic secretory
diarrhea
270420 AR SPINT2
Netherton syndrome 256500 AR SPINT5
Trichohepatoenteric
syndrome
222470; 614602 AR TTC37; SKIV2L
Neonatal inflammation skin
and bowel
614328 AR ADAM17
Kabuki syndrome 602113 AD MML2
Dyskeratosis congenita 613989 AD TERT
GUCY2 dominant negative 614616 AD GUCY2C
Endocrine
Enteric anendocrinosis 610370 AR NEUROG3
Enteric dysendocrinosis 600955 AR PCSK1
X-linked lissencephaly and
mental retardation
300215 X-linked ARX
Mitchell-Riley syndrome 615710 AR RFX6
Autoimmune enteropathy
IPEX syndrome 304790 X-linked FOXP3
CD25 deficiency 606367 AR CD25
STAT5B deficiency 245590 AR STAT5B
Interleukin-10 (ligand/
receptors) deficiencies
613148 AR IL10; IL10RA/B
MALT1 deficiency 615468 AR MALT1
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; IPEX, immune dysfunction, polyendocrinopathy, enteropathy, X-linked; MIM,
Mendelian Inheritance in Man.
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be applied in management of IF; and address foreseeable obsta-
cles and limitations.
INTESTINAL CRYPT STEM CELLS
The small bowel epithelium is organized into two fundamental
structures: villi and crypts (Fig. 1). Villi form functional absorptive
units populated by a diverse group of differentiated cells, includ-
ing enterocytes, goblet, enteroendocrine, tuft, and microfold
cells. Each villus is supported by at least six invaginations,
termed crypt of Lieberku¨hn [21]. The crypt is occupied mainly
by undifferentiated cells, including transit-amplifying (TA) cells;
however, differentiated enteroendocrine and Paneth cells also
reside in the crypt. Wedged between Paneth cells are the crypt
base columnar cells (CBCCs), which, during homeostasis, main-
tain both self-renewal and continuous replacement of the differ-
entiated cells [22].
Early observations with 3H-thymidine uptake in the intestinal
epithelium suggested twomodels ofmultipotent ISCs: CBCCs and
+4 label-retaining cells in mouse models [22, 23]. The approach
used to reconcile the +4/CBCC debate was to identify a reliable
marker that allowed for visualization, isolation, and tracing of
ISC progeny. The G-protein-coupled receptor, Lgr5, was the first
identified specific marker of CBCCs, but additional markers in-
clude Ascl2, Olfm4, Msi1, and Smoc2 (Fig. 2A) [24–29]. Genetic
lineage tracing in mice harboring GFP–IRES–CreERT2 in the
Lgr5 locus demonstrate that CBCCs are actively cycling and
are long-lived cells that self-renew and differentiate into the full
assortment of epithelial cells [24, 30, 31]. Isolated Lgr5+ cells
were subsequently shown to produce enteroid structures in
an in vitro setting, indicating their stem-like function [32].
Although Lgr5+ cells had been established as the "workhorse
stemcells" fueling self-renewal of the intestine, the cells are byno
means hard-wired; they require niche signals and therefore are
particularly prone to injury [33]. Lineage tracing studies with
genes such as Bmi1, Lrig1, Hopx, andmTert, suggests that quies-
cent cells, or a reserve cell population located at the +4 position,
are required to reconstitute the CBCCs after injury [34–37]. Spe-
cifically, when Lgr5+ cellswere ablated, crypts remained intact for
at least a week through repopulation of CBCCs with quiescent
cells [38]. Various acute and chronic injuries resulting in the loss
of the rapidly dividing CBCCs include radiation exposure, enteric
infection, rejection, and inflammation; the surviving progenitor
and/or quiescentdifferentiatedpopulations are thought to revert
back to the vacant stem cell niche at the crypt base, where they
quickly regain ISC identity and restore epithelial renewal (Fig. 2B)
[33, 38–40]. Most research on ISCs and intestinal crypts is from
the murine or Drosophila models, and a significant gap exists in
our understanding of human ISCs.
SIGNALING PATHWAYS IN INTESTINAL EPITHELIAL HOMEOSTASIS
Ligand-induced signaling pathways required for intestinal epithe-
lial homeostasis emanate from numerous cell types that consti-
tute the ISC niche. The dynamic interplay between the ISCs and
the other cells within the niche creates the system necessary
for tissue generation, maintenance, and repair, and for the ulti-
mate design of stem cell therapeutics [41].
Wnt Signaling
In the intestine, canonical Wnt signals from Paneth cells (Wnt3a)
and the surrounding mesenchyme (Wnt2b, Wnt4, Wnt5a) act as
essential short-range signals to maintain the ISC compartment
[42]. CanonicalWnt signaling pathways are activated by the bind-
ing of Wnt-protein ligands to Frizzled-Lrp5/6 receptors, which
pass the biological signal to the protein Dishevelled (Dvl) inside
the cell and stabilized b-catenin. Accumulated b-catenin enters
the nucleus, engaging Tcf transcription factors to activate tran-
scription of Wnt target genes (Fig. 3A). In the absence of a Wnt
Figure 1. Intestinal crypt. Small bowel epithelium is organized into villus and crypts. Lgr5+ crypt base columnar cells are intercalated with
Paneth cells at the crypt base and continuously generate rapidly proliferating transit-amplifying (TA) cells, which occupy the remainder of
the crypt. TA cells differentiate into the various functional cells on the villi (enterocytes, goblet, enteroendocrine, and Paneth cells). The +4
label retaining cells (which occupy the fourth position from the crypt base) can restore the Lgr5+ stem cell compartment following injury.
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stimulus, free cytoplasmic b-catenin displays an exceedingly
short half-life because of the degradation by the ubiquitin/
proteasome pathway. Among the Wnt target genes, cyclin D1
and c-Myc are well-known drivers of proliferation of undifferen-
tiated cells [21]. Wnt signals from Paneth cells and the surround-
ing mesenchyme fuel the ISC compartment for maintenance and
proliferation along the crypt–villus axis [43].
In contrast, several b-catenin-independent noncanonical sig-
naling pathways have been proposed wherein Wnt signaling is
mediated throughFrizzledproteins and receptor tyrosine kinases,
such as Ror2, and are independent from the LRP5/6 coreceptor
[44].Wnt5a illustrates aWnt ligand that signals in a noncanonical
manner. During the crypt regeneration after tissue injury, Wnt5a
augments transforming growth factor-b (TGF-b) signaling to re-
strict epithelial proliferation and promote restoration of the
proper tissue architecture through the induction of cell cycle in-
hibitors, such as p15INK4B [45].
R-spondins (Rspo) are a family of cysteine-rich, thrombospon-
din type I repeat containing proteins that have an essential role in
survival andproliferationofLgr5+ cells in in vivoand invitro settings
[46, 47]. Mice injected with recombinant Rspo1 and transgenic
Rspo gain-of-function mice have dramatic crypt cell proliferation
and expansion of the villus; this highlights Rspo’s potential efficacy
for the treatment of SBS [46]. Lgr5 and its homologs, Lgr4 and Lgr6,
constitute the receptors for Rspo [48]. The Lgr5/Rspo complex
acts by neutralizing Rnf43 and Znrf3, two transmembrane E3 li-
gases that degrade the Wnt receptors from the cell surface
through ubiquitination [49]. Although topical Rspo displayed effi-
cacy in a model of chemotherapy-induced intestinal mucositis,
it is a potent canonicalWnt agonist, and its associationwith a sub-
set of colon cancers has dampened enthusiasm for its potential
therapeutic use in SBS if administered systemically [46, 50].
NOTCH Signaling
Interaction of a Notch receptor with its cell-bound ligands, such
as Dll1 or Dll4, results in proteolytic release of the Notch intra-
cellular domain (NICD) through the actions of the g-secretase
protease. NICD translocate to the nucleus, where it binds the
transcription factor CBF1/Suppressor of Hairless/LAG-1 (CSL),
thus activating transcription of target genes. Notch signaling ac-
tivates expression of Hes1, which transcriptionally represses
Atoh1, the gatekeeper of entry into the secretory lineage in
the gut (Fig. 3B). Simultaneous inactivation of Dll1 and Dll4 fac-
tors expressed by Paneth cells resulted in the conversion of pro-
liferating progenitors into goblet cells, concomitant with loss of
ISCs [51, 52]. In contrast, Wnt signaling represses Notch signal-
ing through direct inhibition of CSL by Dvl [13]. ISCs are exqui-
sitely sensitive to Notch inhibition, whereas Notch signaling
leads to the differentiation of the absorptive lineage, and an ab-
sence of Notch results in secretory lineages [53]. Thus, Notch
and Wnt signaling pathways are integrated to maintain ISCs
and to regulate self-renewal and cell fate of progeny.
Bone Morphogenetic Protein Signaling
Thebonemorphogenetic protein (BMP) signaling pathway acts as
a negative regulator of crypts, although the exact mechanism re-
mains unknown. BMP-2 and -4 ligands are expressed in the mes-
enchyme along the villus [54], whereas BMP inhibitors (Noggin)
are expressed in the mesenchyme around crypts [55]. The en-
gagement of BMP receptors by BMP leads to complexes be-
tween Smad1/5/8 and Smad 4 to repress stemness genes in
the nucleus (Fig. 3C) [56]. Inhibition of BMP signaling in the villi
by overexpression of Noggin results in hyperproliferative and
ectopic crypt formation [54].
Figure 2. Epithelial regeneration in small bowel. (A): During homeostasis, Lgr5+ CBCCs at the crypt base self-renew and differentiate hetero-
geneous epithelial components. The markers expressed in the cell are indicated in the boxes. (B): Acute injury results in the loss of the pro-
liferating Lgr5+ stem cells but preserves the relatively resistant Paneth cell precursors, +4 stem cells, and niche cells. Surviving +4 cells
function as quiescent stem cells to rapidly regenerate the Lgr5+ crypt base columnar cell pool and restore epithelial renewal. Surviving Dll1+
secretory progenitors or other early TA cells fall back into the surviving niche at the crypt base and consequently convert into Lgr5+ stem cells
to restore epithelial renewal. Abbreviations: M, microfold; TA, transit-amplifying.
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Epidermal Growth Factor Signaling
Epidermal growth factor (EGF) signals exert strong mitogenic ef-
fects on ISCs and TA cells by activation of the Ras/Raf/Mek/Erk
signaling axis (Fig. 3D). Luminal EGF is trophic to the small bowel
of parenterally fed rodents, and inhibition ofMek ablates intes-
tinal stem cells [57, 58]. Lrig1 is highly expressed by most crypt
cells and controls ISC homeostasis by negative regulation of
ErbB signaling; its removal leads to expansion of the prolifera-
tive compartment [35, 59].
Summary of Signaling Pathways
In conclusion, both intrinsic and extrinsic signaling controls self-
renewing or asymmetric division of ISCs. Gene-targetingmice ex-
periments have led to remarkable progress in the understanding
of intercellular mechanisms, especially elucidation of the role of
the niche in regulating ISC proliferation and directed differentia-
tion. Wnts are provided by Paneth cells and surrounding mesen-
chyme, whereas Rspo and BMP inhibitors are distinctly provided
fromnonepithelial sources [60]. However, comparedwith epithe-
lial niche cells, such asPaneth cells,wehave an incomplete under-
standing of the nonepithelial niche cells, including intestinal
subepithelial myofibroblasts (ISEMFs), smooth muscle cells of
themuscularismucosa, lymphandvascular endothelial cells, a va-
riety of bone marrow-derived stromal cells, and enteric nervous
system and extracellular matrix (ECM) components, particularly
in humans [61].
INTESTINAL IN VITRO CULTURE
Long-termmaintenance and propagation ofmurine intestinal ep-
ithelial cells were first reported when the cells were cocultured
with native mesenchymal cellular elements in collagen gels in a
growth factor-independent fashion [48]. In contrast, the develop-
ment of a unique serum-free and mesenchymal-free in vitro cul-
ture system to grow 3D enteroids from a single Lgr5+ CBCC for
periods by combining previously defined niche factors (EGF, Nog-
gin, andRspo1 [ENR]) [32]. In addition to culturemedia supporting
the niche signals, laminin-rich 3D matrix (Matrigel, Corning Inc.,
Corning, NY, http://www.corning.com) assists dynamic patterning
and structural self-formation of complex organ buds [62].
The reconstituted small bowel enteroids recapitulate in vivo
intestinal epithelial structures: single stemcells initially form thin-
walled, balloon-like cystic structures (spheroid) and subsequently
form multiple-budding, crypt-like budding structures (enteroid)
[32]. Enteroids contain ISCs, progenitors, and the full array of dif-
ferentiated cells, whereas spheroids consist ofmore ISCs and pro-
genitor cells and less differentiated intestinal epithelial cells.
The location of each cell type in enteroids mimics in vivo intes-
tinal epithelium (Fig. 4).
3D In Vitro Culture of Human Intestinal Epithelium
Although murine small bowel epithelium is culturable with the
addition of specific niche factors (ENR), additional factors are
Figure 3. Signaling pathways regulating intestinal stem cells (ISCs). (A):Wnt signaling positively regulates the self-renewal and proliferation of
ISCs. (B): BMP signaling promotes differentiation of the intestinal epithelium. (C): Notch signaling regulates the proliferation of ISCs and dif-
ferentiation of secretory progenitors. (D): EGF signaling regulates the proliferation of ISCs and transit-amplifying cells by activation of the Ras/
Raf/Mek/Erk signaling axis. Abbreviations: BMP, bonemorphogenetic protein; CSL, CBF1/Suppressor of Hairless/LAG-1; EGF, epidermal growth
factor; EGFR, epidermal growth factor receptor; NICD, Notch intracellular domain.
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required for growth of similar human cells. We successfully grew
human small bowel epithelium in 3DMatrigel seeded on a feeder
layer of ISEMFs with ENR [63]. Moreover, an ISEMF monolayer
was required toachieve growthof enteroidswhen implanted sub-
cutaneously in mice [63]. The GSK inhibitor CHIR99021 and the
E-cadherin stabilizer Y-27632 enabled robust enteroid formation
from crypts or fluorescence-activated cell sorting (FACS)-sorted
ISC cell surfacemarkers [64]. Others reported that besides the ad-
dition of ENR,Wnt3A, nicotinamide, a small molecule inhibitor of
Alk, and an inhibitor of p38were required for long-term culture of
human small and large intestinal epithelium [65]. Human recon-
stituted intestinal enteroids recapitulate digestive, absorptive,
and secretory functions [66].
Fetal Intestinal Epithelium-Derived Culture
Fetal intestinal epithelium is more acquiescent to in vitro culture
than is its adult counterpart. The differentiation of fetal intestinal
epithelium depends on developmental age and intestinal region
[20]. Human andmurine fetal intestinal tissue do not form crypts
andconsist of a series ofundulating villi [20]. Intestinal epithelium
isolated frommurine fetal samples forms spheroids and grows in-
dependently of EGF or Wnt ligands. In contrast, from postnatal
day 15 onward, cultured epithelium forms enteroids that require
EGF and Wnt ligands and resemble adult enteroids. Indeed, the
enteroids originated from the fetal epithelium retain their unique
gene expression pattern after long-term culture, suggesting
that additional exogenous factors are required to mature
[20].g-Secretase inhibitorandWnt3Apromotemurine fetal intes-
tinal spheroids that differentiate into adult-type enteroids [20,
67]. In addition, transplanted murine fetal small bowel spheroids
canbeengrafted into adult colon anddifferentiate into colonic ep-
ithelium [20], whereas adult small bowel enteroids engrafted into
adult colon retain features of the small bowel [19]. These findings
suggest that fetal intestinal epithelium have a plastic character
that differentiate according to niche-specific signals.
Recently, a novel mesenchymal-feeder layer-based culture
condition for human fetal intestinal epithelium has been report-
ed to establish homogeneous clonogenic ISC populations, re-
ferred to as ground-state ISCs [68]. A combination of ISC
niche factors and fibroblast feeder layer preserves the ground
state of fetal ISCs. The ground-state ISCs can efficiently differen-
tiate into villus-crypt structures when they are transferred to an
air-liquid interface (ALI)-baseddifferentiation culture condition.
Although it remains undetermined whether the ground-state
ISC culture condition can be functional for adult intestinal epi-
thelium [68, 69], the sheet-like structure of ALI-differentiated
epithelium may provide an advantage for disease modeling
and regenerative medicine.
Generating Intestinal Tissues From Human Pluripotent
Stem Cells
Recent advancements with pluripotent stem cells, embryonic
(ESCs), or iPSCs have defined the timing of various soluble factors
required to generate human intestinal organoids (HIOs) [70]. In
this system,pluripotent cells are first differentiated intodefinitive
endodermal cells, followedbyhindgut endodermmaturation, but
the eventual differentiated state of the epithelium is more char-
acteristic of early fetal tissue [71–73]. Some have speculated that
the reasons for the immaturity and diminutive sizemay be the in-
sufficient time that the cells have to mature and/or limitations of
oxygen andnutrient diffusion [70, 71]. To improve thematuration
of epithelium derived from pluripotent-derived HIOs, these cells
were engrafted under the murine kidney capsule to enhance
vascularization by host endothelial cells, and after 6 weeks,
HIOs grew significantly larger than controls [74]. Moreover,
the HIOs had more of a mature adult-type crypt-villus architec-
ture, differentiated intestinal cell lineages, and subepithelial
layers. Furthermore, ileocecal resection induced the expansion
of crypts and villi in engrafted HIO-derived tissues [75]. Func-
tional xenograft transplantation could be a possible approach
that promotes the necessary maturation and differentiation
of pluripotent HIOs to model pathologic conditions that mani-
fest in a nonfetal phenotype.
INTESTINAL STEM CELL THERAPY FOR INTESTINAL FAILURE
Stem cell therapy is a promising alternative strategy for overcom-
ing the current limitations of IF treatment, but genetic modifica-
tion of ISCs will be necessary to fully exploit their potential.
Through use of recent culture technology, gene editing of ISCs
is enabled by the highly amenable and reproducible culture of in-
testinal epithelium. The clonogenic capacity and rapid expansion
of spheroids should permit culture of genetically identical popu-
lations of intestinal epithelium. However, optimal methods to
Figure 4. Reconstituted intestinal enteroid culture. Small bowel crypts or Lgr5+ stem cells are isolated and plated into a Matrigel plug with
culture medium containing epidermal growth factor, Noggin, and R-spondin. Enterosphere (spheroid) was generated during days 1–4 after
initial culturing. After days 5–7, spheroid initiates bud formation and forms reconstituted intestinal enteroid structure (scale bar = 100 mm).
Abbreviation: FACS, fluorescence-activated cell sorting.
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expand human ISCs, ablate native in situ ISCs while maintaining
a receptive niche, and optimally engraft genetically manipu-
lated ISCs have yet to be described. If successful engraftment
of modified ISCs into the ablated small bowel niche of IF pa-
tients is possible, autologous ISC transplantationwill be a prom-
ising treatment option.
Gene Editing in Intestinal Enteroids
Although numerous viral and nonviral gene-editing systems have
been developed, optimization has not been described for the use
of human ISCs in gene therapy [76]. Genome-integrating viral vec-
tors are usually characterized by highly efficient and long-term
transgene expression, andwhile safety concerns do exist, current
lentiviral constructs have a low frequency of integration into sites
that predispose to cancer [77]. Spheroids can be transduced by
lentiviruses, thereby allowingmanipulation of geneswithin these
cells, but the transduction of enteroids is very limited [78]. Al-
thoughnonintegrating viruses, such as adenovirus, are also highly
efficient in transduction and are safer, they offer only a limited
duration of transgene expression [79].
Recently, genome engineering with site-specific nucleases to
edit DNA allowed targeted gene knockouts, generated tissue-
specific cell lineage reporters, overexpressed genes from defined
loci, and introduced and repaired point mutations in stem cells
[80]. The CRISPR/Cas9 site-specific nuclease approach for ge-
nome editing has dramatically advanced in the past year and will
likely be the favored approach for gene editing in the coming
years [81]. Indeed, CRISPR/Cas9 editing was used to correct the
CFTR locus by homologous recombination in cultured ISCs of cys-
tic fibrosis patients [17]. The correctedallele is expressedand fully
functional, as measured in clonally expanded enteroids. This
study provides proof-of-concept for gene correction by homolo-
gous recombination in ISCs derived from patients with a mono-
genic defect. However, two main challenges remain for the use
of genetically corrected reconstituted intestinal enteroids in clin-
ical application: thedevelopmentof ISC ablationandengraftment
techniques and the resolution of the safety concerns.
Intestinal Enteroid Transplantation in the Small Bowel
Theprerequisite for ISC therapy for intestinal disorders is success-
ful engraftment of implanted cells. The proof-of-concept that do-
nor ISCs can reconstitute a new intestinal epithelial layer after
ablation was first demonstrated in 2005 when transplantation
of ileal organoids containing crypts and surrounding mesen-
chymewas successfully engrafted intoadenuded jejunal segment
[82, 83]. In adult rats, a long segment of jejunum was isolated,
with its bloodcirculation left intact, and theenterocyteswerepar-
tially ablated by using luminal high-velocity perfusions with EDTA
solutions. Ileal organoids were harvested from neonatal rats and
successfully transplanted into the ablated segments to generate a
neoileum. The recipients subsequently underwent resection of
the native ileum, and the neoileumwas anastomosed in its place.
The neoileum exhibited enhanced taurocholate uptake and ileal
bile acid transporter expression when compared with the native
jejunum. Indeed, the ileal organoid transplantation was capable
of treating a model of bile acid malabsorption [83, 84]. To date,
this is the only description of organoid engraftment into the small
bowel, highlighting the technical challenges of engrafting ISCs in
the mouse.
Reconstituted Intestinal Enteroids Transplantation in
the Colon
More recently, single murine Lgr5+ ISC-derived colonoids were
transplanted into dextran sulfate sodium (DSS)-ablated colonic ep-
ithelium of Rag22/2 immunodeficient mice [18]. The implanted
colonoids constituted a single-layered epithelium, which formed
self-renewing crypts that were functionally and histologically nor-
mal with long-term engraftment. The colonoid transplantation
accelerated the recovery of epithelial barrier function and reversal
of inflammation in the DSS colitis model. Moreover, murine fetal
small bowel-derived spheroids were successfully engrafted into
immunodeficient mice with DSS-induced colonic damage [20]. In-
deed, transplanted murine fetal small bowel-derived spheroids
were incorporated into the regenerating colonic mucosa and dif-
ferentiated into colonic epithelium, underscoring the notion that
fetal ISCs have a plasticity that enables cross-lineage differentia-
tion into cells of engrafted intestine.Moreover, adult mouse small
bowel-derived enteroids were successfully transplanted into
mechanically disrupted rectal mucosa of immunocompetent
mice and retained small bowel features that were distinct from
the colonic epithelium [19]. This interesting finding suggests that
the residual colon could be used to engraft small bowel ISCs in pa-
tients with SBS, thereby enhancing nutrient absorptive capacity.
These studies provide preliminary evidence that reconstituted in-
testinal enteroids could be used as a source for ISC therapy of in-
testinal disorders, maintaining their identity along the gut through
an epithelium-intrinsic mechanism [19].
PROSPECTSOF ISC TREATMENT FORMONOGENIC ENTEROPATHIES
RESULTING IN IF
The replacement of diseased epitheliumwith gene-corrected au-
tologous ISCs or human leukocyte antigen-matched allogenic ISCs
would be feasible therapeutic approaches for IF with severe
monogenic enteropathies. Overexpressing the wild-type form
of the defective gene may be sufficient for treatment. MVID
and CTE are among several monogenetic disorders that would
be feasible to pursue.
MVID is an autosomal recessive disorder characterized by
chronic profuse watery secretory and malabsorptive diarrhea
[3]. The small bowel mucosa demonstrates villus atrophy with
crypt expansion without inflammatory infiltrate. The most com-
mon form of MVID is associated with biallelic mutations of the
MYO5B gene, which codes for a nonconventional motor protein;
the loss-of-function variants result in abnormal intracellular
protein trafficking and defects in recycling of apical vesicles
and have abnormalities of cell polarity. Recent whole-exome se-
quencing from patients with a milder form of MVID showed
biallelic loss-of-function mutations in STX3, which is the encoded
cellular receptor for transport vesicles in enterocytes. In vitro as-
sessment of patient-derived enteroids and overexpression cells
of truncated STX3 recapitulated most characteristics of variant
MVID [85].
Similarly, patients with CTE present with persistent neonatal
diarrhea that is both secretory and malabsorptive in nature. Bi-
opsy of the small bowel demonstrates focal epithelial “tufts,”
with villus atrophy and crypt expansion. CTE is associated with
biallelic loss-of-functionmutations of the EpCAM gene, which en-
codes an epithelial cell adhesion molecule protein, resulting in
isolated congenital diarrhea without associated extra digestive
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symptoms. Specific founder mutations associated with con-
sanguineous pairing of families from the Arabic peninsula and
Mexico are particularly common in patients with CTE and is in
contrast to MVID, which is associated with significant allelic var-
iant heterogeneity [4, 5].
An obvious approach for ISC gene correction of monogenic
disorders, such asMVIDor CTE,would be ex vivo isolation, correc-
tion, and expansion of ISCs and subsequent implantation (Fig. 5).
Specifically, intestinal crypts could be isolated from the mucosal
biopsy specimenof patients using endoscopic biopsy or short seg-
ment of intestine usingminimal invasive surgery. ISCsmay be iso-
lated from crypts by FACS or can simply be expanded in vitro by
using elevated canonicalWnt signaling that promotes the relative
abundance of ISCs. The genetic defect would be edited by using a
CRISPR/Cas9-type approach, and the gene-corrected ISCs would
be expanded in vitro and subsequently engrafted into the seg-
ment of the patient’s small bowel where the native ISCs have
been ablated. Successfully implanted ISCs should be capable of
differentiating into all lineages of epithelium, and normal absorp-
tive and secretory function would be recovered.
Another promising approach may the use of gene transfer
mediated by a recombinant adenovirus-associated viral (AAV)
vector [86]. AAVs are nonenveloped, single-strandedDNA viruses
that replicate only in the presence of helper virus; they are not
currently known to cause disease [87]. The efficiencies of AAV-
mediated gene targeting varies significantly on the basis of the
species, cell type, and AAV capsid serotype. This AAV-mediated
gene targeting has enabled diverse genomic modifications both
in vitro and in vivo, raising the possibility of gene editing of ISCs
while they remain in situ, thereby obviating the ex vivo phase of
isolation, correction, and engraftment [87]. These features
make AAVs an attractive candidate for correcting monogenic
gastrointestinal disorders, particularly if the corrected ISCs
have a growth and survival advantage when compared with
the native ISCs.
The use of AAV for gene therapy is illustrated by its efficacy in
many clinical trials, including those for hemophilia B [88], Leber’s
congenital amaurosis type II [89], choroideremia [90], and lipo-
protein lipase deficiency [91], with the latter obtaining regulatory
approval in the EuropeanUnion in 2012. Indeed, to date, AAVvec-
tors have been used in more than 162 clinical trials worldwide
[92]. While clinical trials using AAV for gene therapy of MVID
and CTE may be an attractive option, AAV vector-mediated gene
transfer must be assessed for themost efficient AAV capsid sero-
type that transduces human ISCs.
CURRENT CHALLENGES FOR INTESTINAL STEM
CELL TRANSPLANTATION
Although rodent models have demonstrated the feasibility of in-
testinal stem cell-based therapies, several gaps and hurdles need
to be addressed to optimize the clinical utility of these therapies,
particularly for the treatment of monogenetic disorders. For in-
stance, we need to improve our understanding of human ISC
and progenitor cell biology, while establishing optimal ablation
and engraftment techniques in a large-animal model, as we con-
tinue to collect preclinical evidence of safety and therapeutic
efficacy.
First, many of the lessons learned from rodent studies do not
necessarily translate to human systems. Because most studies of
ISCs and their niche were conducted in mouse models, we have a
relative incomplete understanding of the human ISCs/progenitor
and niche cells. Certainly compared with the mouse, in vitro cul-
ture for human cells requires additional growth factors and small
Figure 5. Outline of intestinal stem cell (ISC) transplantation as a treatment for patients with intestinal failure caused by monogenic disease.
The intestinal crypts can be isolated from the mucosa of patients by using endoscopic biopsy. Isolated crypts are dissociated into single cell
suspension, and Lgr5+ ISCs are identified by using FACS. In an alternative method, ISCs can be obtained by spheroid, which consists of ISCs
and its progenitors. Gene editing is intended to restore the function of ISCs, including the overexpression of the corrected form of the defective
gene or selective correction of the disease-causing mutation. The gene-corrected ISCs are expanded in an in vitro 3D culture system and trans-
planted into the segment of the patient’s small bowel, where pathologic ISCs are ablated. Successfully engrafted ISCs can differentiate and
reinstate all lineages of epithelium, with normal absorptive and secretory function. Abbreviations: 3D, three-dimensional; FACS, fluores-
cence-activated cell sorting.
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molecules, suggesting that the biological properties of human
cells aremore complex. Among the shortcomings are the absence
of selective markers that identify the various nondifferentiated
cell populations, both for fluorescence-activated cell sorting
and immunofluorescence [64]. We still need to develop lineage
tracing techniques for our human models. In addition, although
we have an inadequate understanding of the nonepithelial niche
cells inmice, certainly the human intestinal niche has barely been
explored. Substantially more research is needed to understand
the intricacies of these human cells before stem cell-based ther-
apies can be appropriately optimized.
Second, to date, regenerative approaches for diffuse intracta-
ble diseases have focused on the development of stem cell trans-
plantation. Certainly a prerequisite is a detailed procurement
plan to obtain a sufficient number of stem cells because a robust
expansion that is sufficient to repopulate the immense surface
area of the small bowel has not been described for adult human
ISCs. Furthermore, although ISCs can be expanded ex vivo in the
presence of growth factors, recombinant proteins are exceed-
ingly expensive. Certainly it may be worth adapting recently
methods described for in vitro expansion of human pancreatic
b cells generated from iPSCs that use a renewable cell source
and a scalable method [93].
Third, efficient methods to enrich for subtypes of ISCs are
lacking, including those isolated from different regions of the
gut or from different developmental ages that might exhibit
varying responses to signaling cues that could affect their
expandability.
Fourth, robustmethods to integrate engrafted ISCs into exist-
ing intestinalmucosa are still underdeveloped. Previous reported
experimental ISC transplantation models in rodents have applied
different techniques, and for use in humans these methods need
to be both safe and carefully standardized. The first step of trans-
plantation is preparing the diseased ISC for ablation and generat-
ing a receptive niche to engraft healthy ISCs. EDTA sequesters
divalent cations, resulting in the separation of epithelium from
its underlying basement membrane, and can be used with soft
serosal compressions or luminal brushings to enhance the extent
and uniformity of epithelial separation along the gut [84]. How-
ever, luminal EDTA may be absorbed and can induce significant
immediate side effects, including hypotension, electrolyte imbal-
ance, and paresthesia. If the intestinal surface area required to
maintain enteral nutrient balance can be estimated, surgical or
endoscopicmucosal excision, endoscopic laser therapy, or photo-
dynamic therapy might be alternative options [94]. Although
these mucosal ablation approaches are invasive procedures,
other novel techniques, such as minimal radiation or the use of
detergents and/or cytotoxic agents, could be explored. There-
fore, large-animal-based preclinical studies will certainly be re-
quired, because animals such as pigs and nonhuman primates
resemble humans with regard to size, an important limitation
of current rodent models [95].
Fifth, ensuring the safety andefficacy of stemcell-basedprod-
ucts is a major challenge. Cells manufactured in large quantities
outside their natural environment can potentially become inef-
fective and induce adverse effects, such as tumors or immune re-
sponses [96]. Moreover, autologous stem cells with gene editing
may enhance such risks. The U.S. Food and Drug Administration
(FDA) and the national regulatory agencies in other countriesmay
havemore stringent precautions, farmore so than formany other
regulated products [96].
Finally, the FDAwill not allow the use of cells that weremain-
tained in Matrigel because it is a poorly defined extract from an
Engelbreth-Holm-Swarm tumor in mice. Of course, Matrigel
mimics the native basal membrane composed of ECMmolecules,
such as laminin, collagen type IV, entactin, and heparan sulfate
proteoglycans, as well as some growth factors, such as TGF-b
and fibroblast growth factor [97].We have used collagen and var-
ious laminins in 2D and 3D culture for reconstituted intestinal
enteroids, but the culture efficiency is lower, and several of these
ECMs are expensive [18]. Certainly hydrogels might be a possible
solution to this problem.
Therefore, among the current limitations of using ISCs for re-
generativemedicine is the need to establish a large-animalmodel
in which the techniques and safety of transplantation methods
may be established, including methods of mucosal ablation,
and the dosing of implanted cell, optimal ex vivo expansion of
ISCs, and the routes of administration may be extrapolated read-
ily to humans.
CONCLUSION
IF is a rare but life-threatening condition resulting from the inabil-
ity to maintain the growth and development with nutrition
obtained via the enteral route. Although PN and allogeneic intes-
tinal transplantation improve the survival of patients with IF, cur-
rent therapies have significant long-term limitations. The recent
development of methods for expansion of human ISCs and iPSCs
has made it possible to reconstitute complex cellular structures
thatmimic thenativebowel in an in vitro setting.Moreover,when
intestinal enteroids were transplanted into suitable donor sites,
they gave rise to a completemucosal epitheliumwith all cell line-
ages, and the appropriate ECM enables the growth potential of
the neo-mucosa. Finally, the development of genome editing
techniques, such as CRISPR/Cas9, has made genetic engineering
of stem cells possible and provides new opportunities to per-
form autologous stem cell transplantation for IF with severe
monogenic enteropathies. Although themethods used to ablate
diseased mucosa, dosing and optimal growth of ISCs, and the
route of administration still require optimization, the replace-
ment of diseased epitheliumwith corrected epitheliumoriginat-
ing from gene editing of autologous stem cells is a feasible
therapeutic approach.
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